MISSISSAUGA, ON, April 12, 2017 /CNW/ - Crescita Therapeutics Inc. (TSX:CTX) (Crescita or the Company), a commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions and diseases and their symptoms, today announced the appointment of Mr. Serge Verreault as President of the Company effective April 17, 2017. Mr. Dan Chicoine will continue as Crescita's Executive Chairman & Interim Chief Executive Officer.
For the past fourteen years, Mr. Verreault has worked at Valeant Canada in a variety of positions. Most recently, Mr. Verreault was the Executive Director of Business Development and a member of the Operating Committee. During his tenure in this role, he also served as the General Manager of Laboratoire Dr Renaud™. Laboratoire Dr Renaud is one of the product lines that Crescita acquired as part of the INTEGA Skin Sciences Inc. acquisition in September 2016.
Mr. Verreault has executed more than thirty licensing and acquisition deals acting in every step of the business development process, from lead generation to integration, and participated in some of the global deals for the Canadian operation at Valeant. Previous to joining Valeant, Mr. Verreault worked at Medicago Inc. and Dismed Inc. Mr. Verreault holds a B.A. and an M.B.A. in International Marketing from Laval University and a Diploma in Nursing.
"We are thrilled that Serge will be joining the Crescita management team," said Dan Chicoine, Crescita's Executive Chairman and Interim CEO. "His experience, proven leadership and management skills will be invaluable as we move forward with our growth strategy of building a profitable and successful North American skincare company serving both the non-prescription and prescription markets."
About Crescita Therapeutics Inc.
Crescita (TSX:CTX) is a publicly traded, Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions and diseases and their symptoms. Crescita owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active drugs into or through the skin. Crescita's board of directors and management team have demonstrated success in building Crescita's predecessor company, Nuvo Research Inc., including developing multiple drugs that are now approved and commercialized and negotiating multiple licensing transactions. For additional information, please visit www.crescitatherapeutics.com.
Certain statements in this press release constitute forward-looking information and/or forward-looking statements (collectively, forward-looking statements) within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to Crescita's future governance plans and the expected benefits of the transaction to Crescita's shareholders. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "believe", "should" or "plans", or similar expressions suggesting future outcomes or events. Such forward-looking statements reflect management's current beliefs and are based on information currently available to management. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those contemplated by such statements. Factors that could cause such differences include, but are not limited to, general business and economic uncertainties and adverse market conditions; uncertainties related to Crescita's ability to realize the anticipated benefits of the acquisition; the expected future attributes and success of Crescita and INTEGA; the successful execution of Crescita's and INTEGA's priorities and strategies; the reliability of Nuvo Research's historical financial information as an indicator of Crescita's historical or future results; as well as other risk factors included in Nuvo Research's Management Information Circular dated December 31, 2015 (the Reorganization Circular) and the most recent Crescita Annual Information Form dated March 29, 2017 under the heading "Risks Factors", and as described from time to time in the reports and disclosure documents filed by Crescita with Canadian securities regulatory agencies and commissions. These and other factors should be considered carefully and readers should not place undue reliance on Crescita's forward-looking statements. As a result of the foregoing and other factors, no assurance can be given as to any such future results, levels of activity or achievements and none of Crescita, INTEGA or any other person assumes responsibility for the accuracy and completeness of these forward-looking statements. Although the forward-looking information contained in this press release is based upon what management believes are reasonable assumptions, there can be no assurance that actual results will be consistent with these forward-looking statements. All forward-looking statements in this press release are qualified by these cautionary statements. The forward-looking statements contained herein are made as of the date of this press release and, except as required by applicable law, Crescita undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
SOURCE Crescita Therapeutics Inc.
For further information: Investor Relations, Email: email@example.com